Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
98 participants
INTERVENTIONAL
2000-10-31
2004-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atorvastatin calcium
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of probable or possible Alzheimer's disease according to NINDS-ADRDA and DSM-IV criteria.
* Not actively participating in another clinical drug trial.
* MMSE range 12-28 at entry.
* Hachinski Modified Ischemic score \< or =4.
* Accompanied by appropriate caregiver who can aid in administration of medication and make assessments.
* Good general health as evidenced by physical, neurological and clinical laboratory examination.
* Education level \> or = 9th grade or equivalent.
* Fluent in the English language.
* Reliable caregiver.
* Able to complete neuropsychological tests.
* Ambulatory.
* On stable doses of medications for the treatment of non-excluded medical conditions for four weeks prior to screening.
* Able to participate in all scheduled evaluations.
* Geriatric Depression Scale \< or = 20.
* Not exceeding 400 IU of Vitamin E for 30 days.
* For patients currently taking donepezil, they must remain on a stable dose for at least three months. Individuals taking stable doses of other cholinesterase inhibitors can be included, but no study subject may initiate use of any cholinesterase inhibitor after entrance to trial.
* Individuals of both sexes over 50 years of age will be eligible.
Exclusion Criteria
* Patients with known or suspected Parkinsons's disease or dementia with Lewy bodies.
* Significant systemic illness (including uncontrolled hypertension) or organ failure.
* History of mental illness within one year or history of significant untreated cardiac or thromboembolic vascular disease (arrythmias, unstable angina, CVA, deep venous thrombosis, or pulmonary embolus).
* Current chronic use of anti-cholinergic medications (anti-histamines, and Artane or Cogentin). Stable doses of anxiolytics, sedatives, hypnotics, antipsychotics and SSRI antidepressants are acceptable. The use of any antipsychotics or tricyclic anti-depressants must be reviewed prior to entry.
* Diagnosis of major depression according to DSM-IV criteria in the last two years.
* Allergies to atorvastatin or HMG CoA reductase inhibitors.
* Pregnant women.
* History of head injury.
* On a cholesterol lowering drug at time of enrollment.
* History of significant liver disease and or elevated transaminases.
* Cholesterol level lower than 90 mg% at initial screening
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Institute for the Study of Aging (ISOA)
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David L Sparks, PhD
Role: PRINCIPAL_INVESTIGATOR
Sun Health Research Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sun Health Research Institute
Sun City, Arizona, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Sparks DL. Intraneuronal beta-amyloid immunoreactivity in the CNS. Neurobiol Aging. 1996 Mar-Apr;17(2):291-9. doi: 10.1016/0197-4580(95)02067-5.
Sparks DL. Coronary artery disease, hypertension, ApoE, and cholesterol: a link to Alzheimer's disease? Ann N Y Acad Sci. 1997 Sep 26;826:128-46. doi: 10.1111/j.1749-6632.1997.tb48466.x.
Sparks DL, Martin TA, Gross DR, Hunsaker JC 3rd. Link between heart disease, cholesterol, and Alzheimer's disease: a review. Microsc Res Tech. 2000 Aug 15;50(4):287-90. doi: 10.1002/1097-0029(20000815)50:43.0.CO;2-L.
Sparks DL, Lopez J, Connor D, Sabbagh M, Seward J, Browne P; Alzheimer's Disease Cholesterol-Lowering Treatment Team. A position paper: based on observational data indicating an increased rate of altered blood chemistry requiring withdrawal from the Alzheimer's Disease Cholesterol-Lowering Treatment Trial (ADCLT). J Mol Neurosci. 2003;20(3):407-10. doi: 10.1385/JMN:20:3:407.
Sparks DL, Connor DJ, Browne P, Sabbagh MN; AD Cholesterol-Lowering Treatment Trial Team. Should the guidelines for monitoring serum cholesterol levels in the elderly be re-evaluated? J Mol Neurosci. 2002 Aug-Oct;19(1-2):209-12. doi: 10.1007/s12031-002-0035-1.
Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Browne P, Wasser D, Johnson-Traver S, Lochhead J, Ziolwolski C. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol. 2005 May;62(5):753-7. doi: 10.1001/archneur.62.5.753.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IA0031
Identifier Type: -
Identifier Source: org_study_id